Evofem Biosciences (EVFM) Competitors

CNS Pharmaceuticals (NASDAQ:CNSP) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Do institutionals & insiders have more ownership in CNSP or EVFM?

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is CNSP or EVFM more profitable?

CNS Pharmaceuticals has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. CNS Pharmaceuticals' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	N/A	-515.32%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Does the MarketBeat Community believe in CNSP or EVFM?

Evofem Biosciences received 214 more outperform votes than CNS Pharmaceuticals when rated by MarketBeat users. However, 71.64% of users gave CNS Pharmaceuticals an outperform vote while only 69.50% of users gave Evofem Biosciences an outperform vote.

Company	Underperform	Outperform
CNS Pharmaceuticals	Outperform Votes 48 71.64%	Underperform Votes 19 28.36%
Evofem Biosciences	Outperform Votes 262 69.50%	Underperform Votes 115 30.50%

Do analysts prefer CNSP or EVFM?

CNS Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 639.64%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has better earnings and valuation, CNSP or EVFM?

Evofem Biosciences has higher revenue and earnings than CNS Pharmaceuticals. Evofem Biosciences is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$18.85M	-$3.75 thousand	0.00
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.62	-0.01

Which has more volatility & risk, CNSP or EVFM?

CNS Pharmaceuticals has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.74, indicating that its share price is 174% less volatile than the S&P 500.

Does the media refer more to CNSP or EVFM?

In the previous week, Evofem Biosciences had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for Evofem Biosciences and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CNS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evofem Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CNS Pharmaceuticals beats Evofem Biosciences on 9 of the 17 factors compared between the two stocks.